The mission and vision of the ACRF Image X Institute is to create, share and apply scientific knowledge to improve human health. We focus on developing and improving anatomic and physiologic cancer imaging methods and integrating these innovations into adaptive medical therapeutic systems, particularly radiation therapy.

A critical step in applying our technology is the translation of our technology through clinical trials. We are involved in clinical trials where Prof Keall, ACRF Image X Institute members and the University of Sydney may hold patents and other intellectual property and may benefit financially from the results of the trials.

We also partner in clinical trials with external companies, including start-ups from our laboratory, in trials where we may benefit financially from the results of the trials. ACRF Image X Institute members work with the University to identify and best manage these conflicts.

Professor Paul Keall

Patents
Inventor on patents and patent applications
Inventor on granted US patents
Inventor on US patent applications

 

Licenses and Assignments

A CT ventilation patent and related IP have been licensed.

Ardos has been assigned image-guided radiation therapy intellectual property.

Leo Cancer Care has licensed and been assigned image-guided radiation therapy methods.

PWR Healthcare has been assigned image-guided radiation therapy intellectual property.

Opus Medical has licensed an audiovisual biofeedback patent.

Standard Imaging has licensed a motion platform design from Virginia Commonwealth University.

SeeTreat has been assigned image-guided radiotherapy methods from the University of Sydney.

Varian has licensed image-guided radiotherapy methods from Stanford University.

Research Agreements

Siemens for four-dimensional imaging research.

New Entities

Founder, 20% shareholder and director of Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.

Founder of Leo Cancer Care, a company developing a real-time image-guided cancer radiotherapy system.

Founder, 50% shareholder and director of SeeTreat Pty Ltd, a company that is advancing image guided cancer radiotherapy.

 

Professor Ricky O’Brien

Research Agreements

Siemens (Principal Investigator with Paul Keall) on four-dimensional imaging research.

Ownership

Founder, 5% shareholder and hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.

 

Kuldeep Makhija

Ownership

Founder, 5% shareholder, part-time employee and hardware and software developer for Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.